Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.52 |
| ▸ | QPCT | Q16769 | 2/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | PRKCI | P41743 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | IDH1 | O75874 | 1/20 | 0.43 |
| ▸ | PLK1 | P53350 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6982150 | 0.87 | TSHR (0.52) | TSHRQPCTGAAKMT2AALDH1A1 | |
| SCHEMBL6977534 | 0.87 | TSHR (0.52) | TSHRQPCTGAAKMT2AALDH1A1 | |
| SCHEMBL6978222 | 0.85 | TSHR (0.50) | TSHRQPCTGSK3BGAAKMT2A | |
| SCHEMBL6972602 | 0.85 | TSHR (0.49) | TSHRQPCTGAAKMT2ASMN1; SMN2 | |
| SCHEMBL6980842 | 0.85 | TSHR (0.49) | TSHRQPCTGAAKMT2AALDH1A1 | |
| SCHEMBL6976772 | 0.84 | QPCT (0.51) | TSHRQPCTGSK3BGAAKMT2A | |
| SCHEMBL6980747 | 0.83 | TSHR (0.48) | TSHRQPCTGAAKMT2AALDH1A1 | |
| SCHEMBL6980755 | 0.82 | TSHR (0.54) | TSHRQPCTGSK3BGAAKMT2A | |
| SCHEMBL6972018 | 0.82 | TSHR (0.47) | TSHRQPCTGAAKMT2AALDH1A1 | |
| SCHEMBL6982552 | 0.82 | ALDH1A1 (0.50) | TSHRQPCTGSK3BGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030199530-A1 | New compounds derived from quinazoline | LES LABORATORIES SERVIER (FR) | 2003-10-23 | — | — | US | disclosed |
| EP-1346992-A1 | Quinazoline derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199530-A1 | New compounds derived from quinazoline | NQO2, XDH, DRD1 | TSHR 3090/4885QPCT 263/4885GSK3B 3383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.